Table 1. Individual Values of KPS and fPV Quantified by DCE-MRI Enhanced With the Polymer MMCM PEG12,000-Gen4-(Gd-DOTA)16 and the MMCM Prototype Albumin-(Gd-DTPA)35 at Baseline and 24 Hours After a Single Intraperitoneal Injection of the Monoclonal Anti-VEGF Antibody Bevacizumab.
| PEG12,000-Gen4-(Gd-DOTA)16 | Therapy | Control | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| Baseline | Follow-up | Baseline | Follow-up | |||||
|
|
|
|
|
|||||
| Tumor | KPS (μL·min·100 cm3) | fPV (%) | KPS (μL·min·100 cm3) | fPV (%) | KPS (μL·min·100 cm3) | fPV (%) | KPS (μL·min·100 cm3) | fPV (%) |
| 1 | 30 | 1.8 | 8 | 2.7 | 29 | 4.5 | 32 | 3.5 |
| 2 | 44 | 4.3 | 0 | 2.8 | 118 | 6.4 | 19 | 3.3 |
| 3 | 36 | 3.0 | 14 | 5.9 | 35 | 5.4 | 15 | 4.1 |
| 4 | 17 | 2.2 | 17 | 3.6 | 21 | 2.5 | 33 | 5.8 |
| 5 | 38 | 2.2 | 0 | 2.7 | 31 | 3.9 | 45 | 2.9 |
| 6 | 22 | 2.2 | 15 | 5.0 | 31 | 5.1 | 47 | 4.4 |
| 7 | 19 | 6.1 | 18 | 2.4 | 26 | 3.4 | 53 | 5.7 |
| Mean ± SD | 29.5 ± 10.4 | 3.1 ±1.6 | 10.4 ± 7.8* | 3.6 ±1.4 | 41 ± 34 | 4.5 ±1.3 | 35 ± 14 | 4.2 ±1.1 |
|
|
|
|||||||
| Therapy | Control | |||||||
|
|
|
|||||||
| Albumin-(Gd-DTPA) | Baseline | Follow-up | Baseline | Follow-up | ||||
|
|
|
|
|
|||||
| Tumor | KPS (μL·min·100 cm3) | fPV (%) | KPS (μL·min·100 cm3) | fPV (%) | KPS (μL·min·100 cm3) | fPV (%) | KPS (μL·min·100 cm3) | fPV (%) |
|
| ||||||||
| 1 | 11 | 3.3 | 0 | 2.8 | 16 | 2.6 | 7 | 2.7 |
| 2 | 45 | 5.2 | 0 | 2.6 | 34 | 4.1 | 10 | 2.4 |
| 3 | 16 | 2.8 | 0 | 3.3 | 27 | 3.3 | 15 | 4.3 |
| 4 | 45 | 6.2 | 0 | 6.5 | 37 | 3.7 | 12 | 1.8 |
| 5 | 35 | 4.6 | 0 | 8.4 | 38 | 3.5 | 19 | 3.0 |
| 6 | 38 | 5.6 | 0 | 3.7 | 13 | 1.9 | 11 | 1.1 |
| Mean ± SD | 32 ± 15 | 4.6 ±1.3 | 0* | 4.5 ± 2.3 | 28 ± 11 | 3.2 ± 0.8 | 12 ± 4 | 2.5 ±1 |
DCE, dynamic contrast-enhanced; fPV, tumor vascularity; KPS, tumor endothelial permeability; MMCM, macromolecular contrast medium; MRI, magnetic resonance imaging; PEG, poly ethylene; SD, standard deviation; VEGF, vascular endothelial growth factor.
*
Significantly different to baseline.